IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA

/PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative...

Related Keywords

China ,Shanghai ,Nanjing ,Jiangsu ,Neuromyelitis Optica ,Equecabtagene Autoleucel ,Owen Wang ,China National Medical Products Administration ,National Medical Products Administration ,Drug Administration ,Neuromyelitis Optica Spectrum Disorder ,Investigator Initiated Trial ,Expanded Disability Status Scale ,Chief Executive Officer ,Chief Medical Officer ,Neuromyelitis Opticaspectrum Disorder ,Optica Spectrum Disorder ,Drug Evaluation ,Iaso Biotherapeutics ,